GLP-1R agonists—the new weapon against obesity?

被引：0
|
作者：
Linda Koch
机构：
来源：
Nature Reviews Endocrinology | 2012年 / 8卷 / 4期
关键词：
D O I：
10.1038/nrendo.2012.13
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：196 / 196
相关论文
共 50 条
  • [31] GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
    Vyron Gorgogietas
    Bahareh Rajaei
    Chae Heeyoung
    Bruno J. Santacreu
    Sandra Marín-Cañas
    Paraskevi Salpea
    Toshiaki Sawatani
    Anyishai Musuaya
    María N. Arroyo
    Cristina Moreno-Castro
    Khadija Benabdallah
    Celine Demarez
    Sanna Toivonen
    Cristina Cosentino
    Nathalie Pachera
    Maria Lytrivi
    Ying Cai
    Lode Carnel
    Cris Brown
    Fumihiko Urano
    Piero Marchetti
    Patrick Gilon
    Decio L. Eizirik
    Miriam Cnop
    Mariana Igoillo-Esteve
    Diabetologia, 2023, 66 : 1306 - 1321
  • [32] Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold
    Tan, Huanbo
    Su, Wencheng
    Zhang, Wenyu
    Zhang, Jie
    Sattler, Michael
    Zou, Peijian
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 607
  • [33] Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
    Chen, Xuetao
    Xu, Shicheng
    Yang, Shuang
    Yu, Zezhou
    Chen, Yali
    Wu, Huidan
    Bao, Qichao
    You, Qidong
    Guo, Xiaoke
    Jiang, Zhengyu
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3386 - 3408
  • [34] Mutagenesis facilitated crystallization of GLP-1R
    Xu, Yueming
    Wang, Yuxia
    Wang, Yang
    Liu, Kaiwen
    Peng, Yao
    Yao, Deqiang
    Tao, Houchao
    Liu, Haiguang
    Song, Gaojie
    IUCRJ, 2019, 6 : 996 - 1006
  • [35] GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
    Gorgogietas, Vyron
    Rajaei, Bahareh
    Heeyoung, Chae
    Santacreu, Bruno J.
    Marin-Canas, Sandra
    Salpea, Paraskevi
    Sawatani, Toshiaki
    Musuaya, Anyishai
    Arroyo, Maria N.
    Moreno-Castro, Cristina
    Benabdallah, Khadija
    Demarez, Celine
    Toivonen, Sanna
    Cosentino, Cristina
    Pachera, Nathalie
    Lytrivi, Maria
    Cai, Ying
    Carnel, Lode
    Brown, Cris
    Urano, Fumihiko
    Marchetti, Piero
    Gilon, Patrick
    Eizirik, Decio L.
    Cnop, Miriam
    Igoillo-Esteve, Mariana
    DIABETOLOGIA, 2023, 66 (07) : 1306 - 1321
  • [36] Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
    Kielgast, Urd
    Holst, Jens J.
    Madsbad, Sten
    CURRENT DIABETES REVIEWS, 2009, 5 (04) : 266 - 275
  • [37] GLP-1 Agonists for Obesity
    Moran, Alyssa J.
    Roberto, Christina A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (08):
  • [38] PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist
    Nakamura, Taichi
    Ito, Tetsuhide
    Uchida, Masahiko
    Hijioka, Masayuki
    Igarashi, Hisato
    Oono, Takamasa
    Kato, Masaki
    Nakamura, Kazuhiko
    Suzuki, Koichi
    Jensen, Robert T.
    Takayanagi, Ryoichi
    LABORATORY INVESTIGATION, 2014, 94 (01) : 63 - 78
  • [39] Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
    Challa, Tenagne Delessa
    Beaton, Nigel
    Arnold, Myrtha
    Rudofsky, Gottfried
    Langhans, Wolfgang
    Wolfrum, Christian
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (09) : 6421 - 6430
  • [40] Fat specific weight loss in diet-induced obesity mouse model when treated with bispecific GLP-1R/GLP-2R agonist vs dual GLP-1R/GIPR agonist
    Oh, T.
    Yang, S. -I.
    Roh, J.
    Sung, R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S325 - S325
12345